# KLOW Peptide Results in the Research Literature > KLOW results: a plain-English register of the headline outcomes from the component studies on KPV, GHK-Cu, BPC-157 and TB-500 — what each arm measured, with citations. The headline outcomes from each component's studies — what the investigators measured, in which species, at which dose, and what they found. The blend has no results of its own. ## Reading the KLOW results board KLOW results means component results. The blend has never been placed in a controlled experiment; it has no outcome table of its own. What this page documents are the headline findings from the four component arms — each clearly attributed to the component and the study that produced it. Nothing here is attributed to the KLOW combination without a combination study to support it. ## TB-500 / thymosin beta-4 results In a rat full-thickness wound model, topical or intraperitoneal thymosin beta-4 increased re-epithelialization by **42% at 4 days** and **up to 61% at 7 days** versus saline. Wound contraction increased by at least 11% by day 7. Collagen deposition and angiogenesis were elevated. As little as **10 picograms** of thymosin beta-4 stimulated keratinocyte migration two- to threefold in cell migration assays [1]. In male Wistar rats with embolic stroke, intraperitoneal thymosin beta-4 at 2 and 12 mg/kg (starting 24 hours post-stroke, then every 3 days for 4 more doses) improved neurological function significantly from day 14 through day 56; 18 mg/kg showed no significant benefit (non-monotonic dose response) [10]. In a Phase 1 human study, full-length synthetic thymosin beta-4 IV up to 1260 mg was well tolerated in 40 healthy volunteers with no dose-limiting toxicities and dose-proportional pharmacokinetics [9]. These results are for the full 43-amino-acid protein; equivalence to the TB-500 heptapeptide fragment is not established. ## BPC-157 results BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical measures (load-to-failure, stiffness), functional recovery, collagen organization and macroscopic appearance; at 10 micrograms, 10 nanograms and 10 picograms per rat IP [2]. In a retrospective case series of 16 patients, intra-articular BPC-157 relieved multiple types of knee pain; **11 of 12** patients on BPC-157 alone and **3 of 4** on BPC-157 plus thymosin beta-4 reported significant improvement — 87.5% overall [11]. A 2025 IV safety pilot — 2 adults — found intravenous BPC-157 up to 20 mg well tolerated with no adverse events and no measurable biomarker changes [6]. A 2024 uncontrolled pilot in 12 patients with interstitial cystitis found complete symptom resolution in 10 of 12; all rated Global Response Assessment 5/5 [15]. A 2025 review states only three pilot studies have examined BPC-157 in humans and rates it investigational [14]. ## GHK-Cu results GHK-Cu stimulated synthesis of collagen, dermatan sulfate, chondroitin sulfate and the proteoglycan decorin in human skin studies. In topical placebo-controlled clinical trials, GHK-Cu formulations increased collagen production in **70% of treated women**, versus 50% for vitamin C and 40% for retinoic acid. Documented clinical improvements in skin laxity, clarity, fine lines, wrinkle depth and density [4]. In a bioinformatic analysis of gene expression, GHK modulated the expression of approximately **31.2% of human genes** at a 50%-or-greater change threshold — increasing 59% of affected genes and suppressing 41%, with strong stimulation of the ubiquitin-proteasome system, DNA-repair genes and antioxidant programs [5]. In rodent behavioral testing, GHK produced anxiolytic (anxiety-reducing) effects, reducing anxiety-like behavior in standardized assays [12]. Plasma GHK levels decline from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60 [4]. ## KPV results In human intestinal epithelial cells (Caco2-BBE and HT29-Cl.19A lines) and Jurkat T cells, nanomolar KPV inhibited NF-kappaB nuclear import and MAPK activation, and reduced secretion of TNF-alpha, IL-6, IL-1beta and IL-8. In DSS- and TNBS-induced colitis in C57BL/6 mice, oral KPV at 100 micromolar in drinking water reduced colitis severity [3]. PepT1-mediated uptake was confirmed as the delivery mechanism — KPV enters inflamed gut cells through the same transporter that normally imports dietary di/tripeptides, at a Km of approximately 160 micromolar [3]. No controlled human efficacy trial of KPV as monotherapy has been published. ## KLOW vs GLOW — what the components say GLOW is a three-peptide blend (GHK-Cu, BPC-157, TB-500) that does not include KPV. KLOW adds KPV as the fourth arm — the NF-kappaB and MAPK inflammatory suppression channel that GLOW lacks. In research terms, the addition of KPV extends the blend's reach into the gut-mucosa and innate-immune suppression nodes that GHK-Cu, BPC-157 and TB-500 do not directly address in their primary study models. No head-to-head study comparing KLOW to GLOW — in cells, rodents or humans — exists. The distinction between the two blends is structural and mechanistic, not empirical. ## What no result covers The KLOW results board has a deliberate gap: the combination itself. No outcome table for the four-peptide blend exists in the literature. The 'results' here are four separate data streams, not one convergent trial. A 2026 sports medicine review of unapproved peptide therapies concludes that animal-model promise does not automatically transfer to human benefit, and that scarce human safety data characterize this class of compound [7]. That review's conclusion is the accurate summary of the KLOW results record. --- Four lit nodes traced along their own studies — an indigo-circuit reading of the peer-reviewed component record, with every gap kept open.